SARS-CoV

CAS No.	Product Name	Inquiry
2647442-13-3	GS-621763 GS-621763 is an orally bioavailable prodrug of GS-441524. The nucleoside metabolite of remdesivir, GS-441524 displays potent anti-SARS-CoV-2 efficacy, and is being evaluated in clinical as an oral antiviral therapeutic for COVID-19.
2647530-73-0	Ensitrelvir Ensitrelvir (S-217622) is the first orally active non-covalent, non-peptidic, SARS-CoV-2 3CL protease inhibitor (IC50=13 nM).
2648089-95-4	AT-9010 triethylamine The active triphosphate metabolite AT-9010 can inhibit SARS-CoV-2 replication.
2698336-82-0	Antiviral agent 5 An intermediate in the numerous antiviral protease inhibitors is the glutamine analogue. Antiviral agent 5 is an intermediate used in antiviral agents targeting 3C and 3CL proteases including SARS-CoV-2 Mpro.
2708934-53-4	CCF0058981 CCF0058981, a non-covalent SARS-CoV-2 3CLpro (SC2) inhibitor (IC50 = 68 nM), can inhibit SARS-CoV-1 3CLpro (SC1) with an IC50 of 19 nM. It has antiviral efficacy and has the potential to study COVID-19.
2710278-53-6	SARS-CoV-2-IN-22 SARS-CoV-2-IN-22 is a SARS-CoV-2 pseudovirus entry inhibitor with an IC50 value of 16.96 µM. SARS-CoV-2 3C-like protease (3CLpro), an enzyme essential for viral replication, is an attractive target for intervention. SARS-CoV-2-IN-11 may lead to the emergence of effective SARS-CoV-2-specific antivirals.
2712126-48-0	Imiquimod-d9 Imiquimod-d9 (R 837-d9) is the deuterium labeled Imiquimod. Imiquimod (R 837), an immune response modifier, is a selective toll like receptor 7 (TLR7) agonist. Imiquimod exhibits antiviral and antitumor effects in vivo. Imiquimod can be used for the research of external genital, perianal warts, cancer and COVID-19.
2719679-31-7	MMT5-14 MMT5-14 is a remdesivir analogue with a higher antiviral activity in four variants of SARS-CoV-2 than Remdesivir (HY-104077).
2721455-52-1	SARS-CoV-2-IN-12 SARS-CoV-2-IN-12 (Compound 27) is a potent SARS-CoV-2-related 3C-like protease inhibitor (Ki=32.1 pM) for preventing SARS-CoV-2 viral replication and that could be useful in the research of COVID-19. SARS-CoV-2 3C-like protease (3CLpro), an enzyme essential for viral replication, is an attractive target for intervention. SARS-CoV-2-IN-11 may lead to the emergence of effective SARS-CoV-2-specific antivirals.
2722634-95-7	SARS-CoV-2-IN-10 SARS-CoV-2 3C-like protease (3CLpro), an enzyme essential for viral replication. SARS-CoV-2-IN-10 may be a potent and nontoxic inhibitor of SARS-CoV-2 3CL protease.
2722635-28-9	SARS-CoV-2-IN-11 SARS-CoV-2 3C-like protease (3CLpro), an enzyme essential for viral replication. SARS-CoV-2-IN-11 may be a potent and nontoxic inhibitor of SARS-CoV-2 3CL protease.
2735704-15-9	INSCoV-600K-1 INSCoV-600K(1) is a potent inhibitor of Mpro (3CLpro). Proteases (PL pro and 3CL pro) are involved with transcription and replication of the virus. INSCoV-600K(1) has the potential for the research of SARS-CoV-2 infection.
2735704-19-3	INSCoV-601I-1 INSCoV-601I(1) is a potent inhibitor of Mpro (3CLpro). Proteases (PL pro and 3CL pro) are involved with transcription and replication of the virus. INSCoV-601I(1) has the potential for the research of SARS-CoV-2 infection.
2735704-33-1	INSCoV-614-1B INSCoV-614(1B) is a potent inhibitor of Mpro (3CLpro). Proteases (PL pro and 3CL pro) are involved with transcription and replication of the virus. INSCoV-614(1B) has the potential for the research of SARS-CoV-2 infection.
2738376-78-6	Amprenavir-d4-1 Amprenavir-d4-1 is deuterium labeled Amprenavir. Amprenavir (VX-478) is a HIV protease inhibitor (Ki=0.6 nM) used to treat HIV infection. Amprenavir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 1.09 μM.
2757194-03-7	FWM-4 FWM-4 is a potent SARS-COV-2 NSP13 helicase enzyme inhibitor.
2757194-04-8	FWM-5 FWM-5 is a potent NSP13 helicase inhibitor. SARS-COV-2 NSP13 helicase enzyme plays crucial role in the virus life cycle.
2757470-18-9	Ensitrelvir fumarate Ensitrelvir fumarate is the first orally active, non-covalent and non-peptidic inhibitor of SARS-CoV-2 3CL protease with an IC50 of 13 nM.
2757970-20-8	SARS-CoV-2-3CLpro-IN-1 SARS-CoV-2 3CLpro-IN-1 (Compound 14c) is a potent inhibitor of SARS-CoV-2 3CLpro. 3CLpro (main coronaviruses cysteine-protease) has been identified as a promising target for the development of antiviral drugs. SARS-CoV-2 3CLpro-IN-1 has the potential for the research of infection diseases.
2758278-51-0	3CPLro-IN-2 3CPLro-IN-2 is a potent and orally active inhibitor of SARS-CoV-2 3CLpro with an IC50 and Ki of 1.55 and 6.09 μM, respectively. 3-Chymotrypsin-like cysteine protease (3CLpro) is an indispensable protein in viral replication and represents an attractive drug target for fighting COVID-19.

※ Please kindly note that our services are for research use only.